Enforced expression of miR-143/145 via systemic intravenous delivery with nanoparticles has been shown to inhibit tumor growth of orthotopic pancreatic xenografts by downregulating K-RAS and RREB-1, respectively [48]. This evidence concerns the gene KRAS and neoplasm.